profit from every $100 of sales.
$0$100
Century Therapeutics
$1.81+7.74% today
+238.4% in 1 year
1-year low $0.461-year high $2.94
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Century Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $5.20 million in 2022 to $109 million in 2025, with -$9.58 million of profit last year.
SalesProfit
Century Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Century Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Century Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 2 | 7 | 109 | |
| – | – | – | – | |
| -124 | -125 | -134 | -11 | |
| -121 | -121 | -121 | 3 | |
| -131 | -137 | -127 | -10 | |
| -2.27 | -2.30 | -1.61 | -0.14 | |
| – | – | – | – | |
| -2,381.8% | -5,600.9% | -2,030.8% | -9.6% | |
| -2,518.4% | -6,115.1% | -1,920.9% | -8.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 487 | 361 | 353 | 224 |
| Cash | 84 | 47 | 58 | 62 |
| Total debt | 49 | 48 | 54 | 44 |
| Total liabilities | 184 | 176 | 192 | 65 |
| 303 | 185 | 161 | 159 | |
| 58 | 59 | 79 | 87 | |
| -29.1% | -45.5% | -49.1% | -4.1% | |
| -43.2% | -74.0% | -78.4% | -6.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 14 | -88 | -110 | -104 | |
| 31 | 14 | 0 | 1 | |
| -17 | -102 | -110 | -105 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 15 | 13 | 7 |
Valuation
- –
- –
- –
- 0.7×
- 3.0×
- –
- 119.3×
- -32.0%
- -2.9%
- 0.0%
Profitability
- 0.0%
- -9.6%
- -8.8%
- 0.0%
- -37.3%
- -36.4%
- -53.2%
- -33.0%
- -37.4%
- –
Growth
- +175.9%
- –
- +5.0%
- –
- +12.0%
Financial health
- 0.1×
- 0.17
- 13.5%
- –
- 10.25
- 10.25
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 948
Bottom 16%of 871
Top 3%of 868
Bottom 2%of 985
What analysts expect
- Average price target
- $3.00
- Range
- $2.00 – $4.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.11 | -0.15 | +26.7% |
| Mar 12, 2026 | -0.25 | -0.28 | +10.7% |
| Nov 13, 2025 | -0.32 | -0.39 | +17.9% |
| Aug 14, 2025 | -0.38 | -0.38 | +0.0% |
| May 15, 2025 | 0.89 | -0.31 | +387.1% |
| Mar 19, 2025 | -0.43 | -0.45 | +4.4% |
| Nov 5, 2024 | -0.37 | -0.46 | +19.6% |
| Aug 8, 2024 | -0.38 | -0.50 | +24.0% |
News
Should You Sell Your Stocks Right Now? Here's What a Century's Worth of History Suggests.Yahoo Finance · Nov 1, 2026Century Communities Non-GAAP EPS of $1.01 misses by $0.21, revenue of $864.4M misses by $93.7MSeeking Alpha · Oct 28, 2026Century Next Financial GAAP EPS of $2.41, revenue of $11.37MSeeking Alpha · Oct 23, 2026Century Aluminum gains after Einhorn pitch at Robin Hood conferenceSeeking Alpha · Oct 21, 2026They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record paceCNBC · Oct 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
69Pass
Philip Fisher
30No pass
Peter Lynch
47No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
25No pass
Questions about Century Therapeutics
Is Century Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Century Therapeutics AI analysis
What does Century Therapeutics do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. It is in Biotechnology.
Does Century Therapeutics pay a dividend?
No. Century Therapeutics does not pay a dividend at the moment.
Is Century Therapeutics stock halal?
Questionable. Century Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Century Therapeutics stock done over the past year?
Up 238.4% over the past twelve months, to $1.81. It traded between $0.46 and $2.94 and is 38.4% below its high.
Who are Century Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Century Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.